Shawn Yu

This study identifies PRAME as a therapeutic target in NUT carcinoma, showing its high expression and susceptibility to T-cell mediated cytotoxicity via PRAME epitopes presented by HLA Class I molecules.

This paper designs orthogonal TCR β interfaces to prevent mispairing in dual-TCR therapeutics, achieving high pairing fidelity and demonstrating enhanced potency in targeting cancer antigens.